A New Rapid-Acting Antidepressant | Zendy

John H. Krystal | Zendy; Dennis S. Charney | Zendy; Ronald S. Duman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A New Rapid-Acting Antidepressant

Author(s) -

John H. Krystal,

Dennis S. Charney,

Ronald S. Duman

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.02.033

Subject(s) - antidepressant , biology , depression (economics) , ketamine , bench to bedside , treatment resistant depression , pharmacology , bioinformatics , neuroscience , medicine , medical physics , hippocampus , economics , macroeconomics

The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research